From GlobeNewswire: 2025-03-11 16:05:00

In 2024, SIGA Technologies reported $133 million in product sales, with $70 million in pre-tax operating income and $59 million in net income. The company’s financial strength is reflected in its second consecutive year of product revenue growth. A conference call to discuss corporate updates will be held today at 4:30 PM ET.

Key highlights from the financial results include $79.8 million in product sales for the fourth quarter of 2024, with total revenues amounting to $81.4 million. Operating income for the year ended December 31, 2024, was $70 million, with net income reaching $59.2 million. The company also received procurement orders from 30 countries for oral TPOXX.

In January 2025, TPOXX received regulatory approval in Japan for the treatment of various diseases. SIGA’s flagship product has been approved in multiple countries for the treatment of smallpox and related conditions. The company continues to focus on developing innovative medicines to combat infectious diseases globally.

SIGA Technologies will host a conference call and webcast today at 4:30 PM ET to provide a business update. Participants can access the call by dialing the provided numbers or by visiting the company’s website for a live webcast. A replay of the call will be available for two weeks for those unable to join the live session.



Read more at GlobeNewswire:: SIGA Reports Financial Results for Three and Twelve Months